NCT00396331 · MORE INFO

Limitations, agreements, and source contact

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts · Source last updated 2014-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: PI agrees to submit the draft of any proposed public release or proposed publication to Genzyme and Genzyme may review the proposed public release or draft of the publication for up to 30 days prior to submission for public release, presentation or use. PI agrees (1) to withhold submission for an additional period not to exceed 60 days to allow Genzyme to take action to protect patent rights or trade secret rights (2) to give due consideration to any editorial comments of Genzyme.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: medinfo@genzyme.com
organization: Genzyme
title: Medical Monitor

Complete source fields

certain Agreement

other Details: PI agrees to submit the draft of any proposed public release or proposed publication to Genzyme and Genzyme may review the proposed public release or draft of the publication for up to 30 days prior to submission for public release, presentation or use. PI agrees (1) to withhold submission for an additional period not to exceed 60 days to allow Genzyme to take action to protect patent rights or trade secret rights (2) to give due consideration to any editorial comments of Genzyme.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: medinfo@genzyme.com
organization: Genzyme
title: Medical Monitor

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice